LONDON (Reuters) - British researchers said on Thursday they had identified a gene linked to bladder cancer that could improve the treatment of the disease.
“This is a very exciting development. E2F3 is the missing link in our knowledge of the disease,” said Professor Colin Cooper of Britain’s Institute of Cancer Research.
The E2F3 gene is involved in controlling the division of human cells. Cooper and his colleagues, reporting in the journal Oncogene, found that overexpression of E2F3 was associated with cell proliferation and the development of bladder cancer.
When they measured the amount of E2F3 protein in bladder cancer cells in laboratory tests they found it corresponded to the grade or seriousness of the tumour. Grade 1 bladder cancer cells had smaller amounts of the protein, while cells of a higher grade had increased levels.
“These findings will boost the development of new treatments to target bladder cancer as well as predicting the aggressiveness of a particular cancer, leading to tailor-made, more effective treatments for each individual patient,” Cooper said in a statement.
Bladder cancer is the ninth most common cancer worldwide. The disease kills about 130,000 people worldwide each year and 330,000 new cases are reported annually.
Smoking is the single most important cause of bladder cancer, accounting for 65 percent of male cases and 30 percent of female cases, according to the International Agency for Research on Cancer in Lyon, France.
Source: Oncogene 2004. [ Google search on this article ]
MeSH Headings: Bladder Neoplasms : Neoplasms : Neoplasms by Site : Urogenital Neoplasms : Urologic Neoplasms : Diseases Copyright © 2002 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
